Cardio Diagnostics (CDIO) and Its Competitors Financial Comparison

Cardio Diagnostics (NASDAQ:CDIO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Cardio Diagnostics to similar companies based on the strength of its profitability, analyst recommendations, risk, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cardio Diagnostics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1	0	0	0	1.00
Cardio Diagnostics Competitors	9793	15074	45366	1575	2.54

As a group, “Biotechnology” companies have a potential upside of 101.50%. Given Cardio Diagnostics’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Cardio Diagnostics has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Cardio Diagnostics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cardio Diagnostics	$10,000.00	-$6.50 million	-0.56
Cardio Diagnostics Competitors	$727.61 million	$12.25 million	-9.81

Cardio Diagnostics’ competitors have higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Cardio Diagnostics has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Cardio Diagnostics’ competitors have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Profitability

This table compares Cardio Diagnostics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Cardio Diagnostics Competitors	-9,051.23%	-201.20%	-30.64%

Summary

Cardio Diagnostics competitors beat Cardio Diagnostics on 10 of the 13 factors compared.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.